Aquestive Therapeutics CEO sells $35,413 in company stock
The CEO of Aquestive Therapeutics, Daniel Barber, sold 8,257 shares of the company's common stock for a total of $35,413 on May 15, 2026. This transaction follows a 75% stock return over the past year, though the shares are down 35% year-to-date. The company recently surpassed Q1 2026 earnings expectations and analysts maintain a bullish outlook.
Aquestive Therapeutics (Nasdaq:AQST) - Stock Analysis
This article provides a detailed stock analysis of Aquestive Therapeutics (AQST), highlighting its financial performance, future growth prospects, and analyst ratings. It discusses the company's key products, including Anaphylm (epinephrine sublingual film) and Libervant (diazepam buccal film), and traces the regulatory journey and market positioning of these drugs. The analysis also covers recent news, earnings guidance, and significant corporate developments, alongside competitor information and historical stock performance.
Aquestive Says It’s on Track to Launch Anaphylm Studies for FDA
Aquestive Therapeutics announced it is moving forward with studies required by the FDA for its epinephrine film, Anaphylm, and plans to resubmit its application in the fall of 2026. The FDA had previously declined approval due to user errors in opening the pouch and incorrect placement of the film. Aquestive is awaiting FDA review of its study protocol and anticipates having study results by August to address these concerns, aiming for approval for use in adults and children over 66 pounds.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2026 Earnings Call Transcript
Aquestive Therapeutics (NASDAQ:AQST) discussed its Q1 2026 financial results and provided updates on its key product Anaphylm and pipeline asset AQST-108. The company reiterated its expectation for a Q3 resubmission of Anaphylm's NDA to the FDA, contingent on timely feedback, and highlighted progress in securing a new debt facility and preparing for commercial launch. Additionally, early Phase I data for AQST-108 showed promising directional signals for dermatological indications.
Aquestive Therapeutics (AQST) Q1 Loss Per Share Narrows Challenging Bearish Narratives
Aquestive Therapeutics (AQST) reported Q1 2026 revenue of US$14.4 million and a narrowed EPS loss of US$0.07, an improvement from Q1 2025's US$0.24 loss. Despite growing revenue, the company continues to incur significant losses, with trailing twelve-month net loss at US$68.9 million. The stock trades at a high P/S multiple, indicating investor confidence in future profitability, but analysts note the slow pace of loss reduction and negative shareholder equity.
Aquestive Therapeutics: Q1 Earnings Snapshot
Aquestive Therapeutics Inc. (AQST) reported a first-quarter loss of $8.1 million, or 7 cents per share, which exceeded Wall Street expectations. The company also posted revenue of $14.4 million, surpassing analyst forecasts. Shares of Aquestive Therapeutics were trading significantly higher than a year ago.
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics announced its first-quarter 2026 financial results, highlighting a 66% revenue increase to $14.4 million and a reduced net loss of $8.1 million. The company reaffirmed its plan to resubmit the Anaphylm™ sublingual film NDA in Q3 2026 and provided updates on its AQST-108 topical gel and a new $150 million debt facility. Aquestive's 2026 financial guidance remains unchanged, projecting $46 to $50 million in total revenue.
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics announced its first quarter 2026 financial results, reporting a significant increase in total revenues to $14.4 million, up 66% from the previous year. The company reaffirmed its guidance to resubmit the Anaphylm™ New Drug Application (NDA) in Q3 2026 and provided updates on its AQST-108 phase 1 study, its global regulatory strategy for Anaphylm, and a new $150 million debt facility with Oaktree Capital Management, L.P. The net loss for the quarter substantially decreased to $8.1 million from $22.9 million in Q1 2025.
Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Inc. has entered into a five-year term loan facility for up to $150 million. This financial arrangement was made on May 12, 2026, and was disclosed in an SEC filing.
Aquestive Therapeutics Inc - enters five-year term loan facility of up to $150 million on May 12, 2026 - SEC filing
Aquestive Therapeutics Inc. has announced that it entered into a five-year term loan facility for up to $150 million on May 12, 2026. This information was disclosed in an SEC filing. The article provides this key financial update along with other recent company news and financial data.
12 Health Care Stocks Moving In Wednesday's After-Market Session - Aquestive Therapeutics (NASDAQ:AQST)
This article details 12 health care stocks that experienced significant movement in Wednesday's after-market session. Several companies, including Staar Surgical, Precision Optics Corp, and Aquestive Therapeutics, saw their shares rise following recent earnings reports. Conversely, MDxHealth, Doximity, and DarioHealth were among those whose stocks declined in the same period.
BRIEF-Aquestive Therapeutics, Inc. Q1 Revenue USD 14.446 Million Vs. IBES Estimate USD 10.9 Million
Aquestive Therapeutics, Inc. reported its Q1 revenue at USD 14.446 million, significantly surpassing the IBES estimate of USD 10.9 million. This brief financial update indicates stronger-than-expected performance for the company in the first quarter.
Aquestive Therapeutics (AQST) trims Q1 loss and secures $150M Oaktree debt facility
Aquestive Therapeutics reported a significantly improved Q1 2026, narrowing its net loss to $8.1 million from $22.9 million year-over-year, driven by increased revenue and reduced expenses. The company also secured a new five-year, $150 million debt facility with Oaktree Capital Management, which refinances existing debt and provides capital for the potential launch of its lead allergy drug, Anaphylm. Aquestive reaffirmed its 2026 guidance, expecting total revenue of $46–$50 million and a non-GAAP adjusted EBITDA loss of $30–$35 million.
Aquestive Therapeutics Signs New $150 Million Debt Facility
Aquestive Therapeutics has secured a new $150 million debt facility. This announcement, made by MT Newswires, also briefly mentions Unity Software's financial results for the fourth quarter, where the company reported a significant increase in revenue to $609 million but a quarterly loss of 66 cents per share.
Aquestive Therapeutics sees $150M debt refinancing
Aquestive Therapeutics has secured a new $150 million debt facility with Oaktree Capital Management, L.P., refinancing its existing debt. This deal provides increased financial flexibility to support the potential launch of Anaphylm, pending FDA approval. The new facility reduces principal debt repayments over the next three years and lowers interest rates.
Aquestive secures $150 million debt facility with Oaktree By Investing.com
Aquestive Therapeutics Inc. has secured a new $150 million debt facility from Oaktree Capital Management, refinancing its existing debt and reducing its interest rate. The agreement provides financial flexibility, with funds tied to FDA approval of Anaphylm and sales milestones. This comes after a reported Q4 2025 net loss but a reaffirmed plan to resubmit the New Drug Application for Anaphylm.
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Aquestive Therapeutics has completed a $150 million debt refinancing facility with Oaktree Capital Management, L.P., aiming to provide more flexibility for funding the potential launch of Anaphylm™, if approved by the FDA. The new agreement repays existing debt and reduces principal repayments for the next three years, while also lowering the interest rate. This strategic move is expected to support Aquestive's growth and advance its pipeline of innovative medicines.
Earnings Preview: AQST to Report Financial Results Post-market on May 13
Aquestive Therapeutics (AQST) is scheduled to report its financial results for the quarter ending March 2026 after the market closes on May 13. Analysts project the company to report a per-share loss of $0.21. Investors will be keen to hear management's commentary on the earnings call.
AQST DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Aquestive Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged federal securities law violations. The lawsuit claims that Aquestive Therapeutics made false and misleading statements regarding the approval and launch timeline for its Anaphylm (dibutepinephrine) sublingual film, particularly concerning human factors and regulatory approval risks for its New Drug Application (NDA). Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of May 4, 2026.
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
Aquestive Therapeutics will report its first-quarter financial results for 2026 and provide business updates on May 13, 2026, after market close. Following this, management will host a conference call for investors on May 14, 2026, at 8:00 a.m. ET, with registration required to participate. The webcast of the call will be available on the Investors section of Aquestive's website.
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced it will report its first-quarter 2026 financial results after market close on May 13, 2026. Management will host a conference call for investors on May 14, 2026, at 8:00 a.m. ET to discuss the results and provide business updates. The company is advancing medicines through innovative science and delivery technologies, including Anaphylm™ for severe allergic reactions and AQST-108 for dermatological conditions.
Aquestive Therapeutics to Report First Quarter 2026
Aquestive Therapeutics announced it will report its first quarter 2026 financial results and business updates after market close on May 13, 2026. Management will host a conference call for investors on May 14, 2026, at 8:00 a.m. ET to discuss the results and recent developments. The company is advancing several product candidates, including Anaphylm™ for severe allergic reactions.
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) alleging federal securities law violations. The lawsuit claims that Aquestive Therapeutics made false and misleading statements regarding the approval and launch timeline for its New Drug Application for Anaphylm. Investors who purchased Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026, are encouraged to join the case, with a lead plaintiff deadline of May 4, 2026.
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP has issued a final deadline alert for investors in Aquestive Therapeutics (AQST) to seek lead plaintiff status in a federal securities class action lawsuit by May 4, 2026. The lawsuit alleges that Aquestive and its executives made false and misleading statements about the company's NDA for Anaphylm, specifically regarding human factors involved in its use. This led to a significant stock price drop on January 9, 2026, after the FDA identified deficiencies in the NDA.
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP has issued a final deadline alert for investors in Aquestive Therapeutics (AQST) regarding a securities class action lawsuit. Investors who purchased or acquired Aquestive securities between June 16, 2025, and January 8, 2026, are encouraged to contact the law firm to discuss their legal rights, as the lead plaintiff deadline is May 4, 2026. The lawsuit alleges that Aquestive and its executives made misleading statements and failed to disclose critical information concerning the FDA's review of its NDA for Anaphylm, leading to a significant stock price drop on January 9, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) alleging that the company made false and misleading statements regarding the approval timeline for its drug Anaphylm. Investors who purchased Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026, are encouraged to join the class action by May 4, 2026. The firm claims that Aquestive overstated the likelihood of approval for Anaphylm and concealed material human-factors issues impacting regulatory success.
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) alleging that the company made false and misleading statements regarding the approval timeline for its drug Anaphylm. Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit to recover damages by requesting to be appointed as lead plaintiff by May 4, 2026. The firm, which operates on a contingency fee basis, asserts that Aquestive overstated its confidence in the drug's approval, particularly regarding human factors issues related to the sublingual film's use.
AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Rosen Law Firm is reminding investors who purchased Aquestive Therapeutics, Inc. (AQST) securities between June 16, 2025, and January 8, 2026, about the May 4, 2026 lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Aquestive made misleading statements and failed to disclose human factors issues related to its New Drug Application for Anaphylm. Investors are encouraged to contact Rosen Law Firm for more information on joining the class action.
AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds purchasers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities during the Class Period of June 16, 2025, to January 8, 2026, about the lead plaintiff deadline of May 4, 2026. The lawsuit alleges that Aquestive made false or misleading statements and failed to disclose issues regarding the human factors involved in the use of its Anaphylm New Drug Application. Investors who suffered damages are encouraged to join the class action.
AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors ...
Rosen Law Firm is encouraging investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) who purchased securities between June 16, 2025, and January 8, 2026, to contact them regarding a lead plaintiff deadline of May 4, 2026. A class action lawsuit has been filed alleging that Aquestive Therapeutics made false and/or misleading statements concerning its New Drug Application for Anaphylm, causing investors to suffer damages. The firm offers guidance to investors on how to join the class action and highlights its track record in securities class action settlements.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Stock Dropped Over 37 Percent: Levi & Korsinsky
Levi & Korsinsky is alerting investors about a securities fraud lawsuit against Aquestive Therapeutics, Inc. (AQST). Institutional investors who held AQST shares between June 16, 2025, and January 8, 2026, are encouraged to evaluate lead plaintiff opportunities. The lawsuit alleges that Aquestive disseminated misleading statements regarding the regulatory approval of its Anaphylm product, leading to a stock drop of over 37% on January 9, 2026.
AQST DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - AQST
Rosen Law Firm is encouraging investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) to secure legal counsel before the May 4, 2026, lead plaintiff deadline in a securities class action. The lawsuit alleges that Aquestive made misleading statements regarding its New Drug Application for Anaphylm, specifically minimizing human factors involved in the sublingual film's use and deployment. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, may be entitled to compensation.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff
The Gross Law Firm is notifying shareholders of Aquestive Therapeutics, Inc. (AQST) about a lead plaintiff deadline of May 4, 2026. This pertains to a class action lawsuit alleging that Aquestive Therapeutics made materially false and misleading statements regarding its New Drug Application for Anaphylm, leading to a significant stock price decline. Shareholders who purchased AQST shares between June 16, 2025, and January 8, 2026, are encouraged to contact the firm.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims Pattern Of Harm: SueWallSt
SueWallSt encourages investors of Aquestive Therapeutics, Inc. (AQST) who suffered losses between June 16, 2025, and January 8, 2026, to reach out as a securities fraud lawsuit has been filed. The lawsuit alleges that Aquestive management made misleading statements about the FDA approval process for its drug Anaphylm, concealing known deficiencies. Investors have until May 4, 2026, to apply for lead plaintiff in the class action.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST
Pomerantz LLP has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) after the company's stock price fell significantly following an FDA letter identifying deficiencies in its Anaphylm NDA, effectively delaying approval. Investors who incurred losses on their Aquestive securities are encouraged to contact Pomerantz LLP and have until May 4, 2026, to apply to be lead plaintiff. The lawsuit alleges securities fraud and other unlawful business practices by Aquestive's officers and/or directors.
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP is reminding investors of Aquestive Therapeutics (AQST) that the deadline to seek the role of lead plaintiff in a federal securities class action is May 4, 2026. The lawsuit alleges that Aquestive and its executives made false and misleading statements about the company's NDA for Anaphylm, specifically regarding human factors in its use and deployment, leading to a significant stock price drop on January 9, 2026, after the FDA identified deficiencies. Investors who suffered losses while holding Aquestive securities between June 16, 2025, and January 8, 2026, are encouraged to contact the law firm to discuss their legal rights.
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aquestive Therapeutics, Inc. for alleged violations of federal securities laws. The lawsuit claims that Aquestive Therapeutics made materially false and misleading statements regarding the approval and launch timeline for its Anaphylm sublingual film, specifically concerning its New Drug Application (NDA) and the associated human-factors issues. Investors who purchased Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026, are encouraged to join the case and have until May 4, 2026, to request to be appointed as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges Aquestive
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) alleging federal securities law violations. The lawsuit claims Aquestive made false and misleading statements regarding the approval timeline for its drug Anaphylm, specifically related to human factors risks. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the suit and have until May 4, 2026, to request to be appointed lead plaintiff.
AQST Shareholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged violations of federal securities laws. The lawsuit claims Aquestive made false and misleading statements about the approval timeline for its Anaphylm NDA, failing to disclose significant human factors risks impacting regulatory approval. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit and have until May 4, 2026, to request to be appointed as lead plaintiff.
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive gave the false impression that its New Drug Application for Anaphylm would be approved by the January 31, 2026 PDUFA date, despite the FDA identifying deficiencies. Investors who suffered losses have until May 4, 2026, to apply to be appointed as lead plaintiff.
AQST DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - AQST
The Rosen Law Firm is reminding investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) who purchased securities between June 16, 2025, and January 8, 2026, about the May 4, 2026, deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Aquestive made false and misleading statements regarding its New Drug Application for Anaphylm, specifically minimizing the significance of human factors in its product's use. Investors who suffered damages are encouraged to contact the firm.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Stock Dropped Over 37 Percent: Levi & Korsinsky
Levi & Korsinsky is alerting investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) about a securities fraud lawsuit. Investors who held AQST shares between June 16, 2025, and January 8, 2026, and experienced losses following a 37% stock drop on January 9, 2026, may seek to become lead plaintiffs. The lawsuit alleges that Aquestive disseminated misleading statements regarding the regulatory approval timeline for its Anaphylm product, artificially inflating the company's stock price.
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has announced that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged violations of federal securities laws. The lawsuit claims that the company made false and misleading statements regarding the approval and launch timeline for its Anaphylm NDA. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to contact the firm by May 4, 2026, to discuss leading the lawsuit.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.
Levi & Korsinsky, LLP is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) regarding potential securities fraud. The lawsuit alleges that Aquestive failed to adequately disclose specific deficiencies in its Anaphylm NDA between June 16, 2025, and January 8, 2026, leading to a significant stock drop after the FDA flagged these issues. The firm argues that generic risk warnings were insufficient given the company's alleged knowledge of concrete problems, and investors now have until May 4, 2026, to seek to lead the class action.
AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit - Contact The Gross Law Firm
The Gross Law Firm is issuing a shareholder alert for investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) who incurred losses between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive made misleading statements regarding its Anaphylm (Dibutepinephrine) sublingual film's New Drug Application, failing to disclose significant human factors issues. Following an FDA letter identifying deficiencies, Aquestive's stock price dropped over 37% in one day, and shareholders are encouraged to contact the firm by May 4, 2026, to seek lead plaintiff appointment.
Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Aquestive Therapeutics, Inc. The lawsuit alleges that Aquestive made misleading statements regarding the approval of its Anaphylm drug, failing to disclose FDA deficiencies that delayed its launch. Investors who purchased securities between June 16, 2025, and January 8, 2026, have until May 4, 2026, to file a lead plaintiff motion.
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP is reminding investors of Aquestive Therapeutics (AQST) about the May 4, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Aquestive Therapeutics made false and/or misleading statements regarding its NDA for Anaphylm, specifically by minimizing issues related to the human factors involved in the sublingual film's use, administration, and labeling. This follows a significant stock drop on January 9, 2026, after the FDA identified deficiencies in the Anaphylm NDA.
AQST DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - AQST
Rosen Law Firm is encouraging investors of Aquestive Therapeutics, Inc. to secure legal counsel before the May 4, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Aquestive made misleading statements regarding its New Drug Application for Anaphylm, specifically minimizing issues with human factors in its sublingual film's use. Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.
Levi & Korsinsky, LLP is investigating Aquestive Therapeutics, Inc. (AQST) regarding potential securities fraud. The investigation focuses on whether the company made adequate risk disclosures concerning FDA deficiencies with its Anaphylm NDA, which led to a significant stock drop. Investors who suffered losses between June 16, 2025, and January 8, 2026, are encouraged to seek a case evaluation as the lead plaintiff deadline is May 4, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its officers. The lawsuit alleges that the company made false and misleading statements regarding the approval and launch timeline for its New Drug Application (NDA) for Anaphylm, specifically downplaying human factors risks. Investors who purchased Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit, with a deadline of May 4, 2026, to request lead plaintiff status.
